Atea Pharmaceuticals, Inc. has placed 12 500 000 shares of common stock in an IPO priced $24 per share, which corresponds to the upper limit of the previously announced range ($22-24). Besides, Atea has granted the underwriters a 30-day option to purchase up to 1 875 000 shares of common stock in the IPO at the public offering price.
The trading debut will take place on October 30, 2020 on the Nasdaq Global Select Market under the ticker symbol “AVIR”.